Cognition Therapeutics, Inc.
CGTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4 | $11 | $11 | $8 |
| G&A Expenses | $0 | $2 | $3 | $3 |
| SG&A Expenses | $3 | $2 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6 | $14 | $14 | $11 |
| Operating Income | -$6 | -$14 | -$14 | -$11 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $7 | $5 | $3 |
| Pre-Tax Income | -$5 | -$7 | -$8 | -$8 |
| Tax Expense | – | $0 | $0 | $0 |
| Net Income | -$5 | -$7 | -$8 | -$8 |
| % Margin | – | – | – | – |
| EPS | -0.06 | -0.11 | -0.14 | -0.17 |
| % Growth | 45.5% | 21.4% | 17.6% | – |
| EPS Diluted | -0.06 | -0.11 | -0.14 | -0.17 |
| Weighted Avg Shares Out | 78 | 64 | 62 | 46 |
| Weighted Avg Shares Out Dil | 78 | 64 | 62 | 46 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$7 | -$8 | -$8 |
| % Margin | – | – | – | – |